{"id":71515,"date":"2026-05-20T10:40:00","date_gmt":"2026-05-20T10:40:00","guid":{"rendered":"https:\/\/medsbase.com\/foxo4-dri\/"},"modified":"2026-05-21T07:14:08","modified_gmt":"2026-05-21T07:14:08","slug":"foxo4-dri","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/foxo4-dri\/","title":{"rendered":"FOXO4-DRI (FOX04-DRI) \u2014 Senolytick\u00fd v\u00fdzkumn\u00fd peptid"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Rychl\u00e1 odpov\u011b\u010f \u2014 Co je FOXO4-DRI?<\/h3>\n<p style=\"margin: 0;\"><strong>FOXO4-DRI<\/strong> (tak\u00e9 ps\u00e1no FOX04-DRI; \u201cDRI\u201d = D-Retro-Inverso) je syntetick\u00fd peptid o ~28 aminokyselin\u00e1ch <strong>senolytick\u00fd peptid<\/strong> vyvinut\u00fd Baarem, Brandtovou, de Keizerem, Demariou, Campisiovou a kolegy na Erasmus University Medical Center a publikovan\u00fd v p\u0159elomov\u00e9 <em>Cell<\/em> studii \u201cC\u00edlen\u00e1 apopt\u00f3za senescentn\u00edch bun\u011bk obnovuje tk\u00e1\u0148ovou homeost\u00e1zu v reakci na chemotoxicitu a st\u00e1rnut\u00ed\u201d (Baar et al., b\u0159ezen 2017). Peptid je D-aminokyselinov\u00e1 retro-inverzn\u00ed verze fragmentu transaktiva\u010dn\u00ed dom\u00e9ny FOXO4 (odpov\u00edd\u00e1 zbytk\u016fm ~86\u2013100 lidsk\u00e9ho FOXO4). Sekvence v konven\u010dn\u00edm \u010dtec\u00edm po\u0159ad\u00ed: <strong>LTLRKEPASEIAQSILEAYSQNGWANRRSAGGNTPS<\/strong> (v\u0161echny D-aminokyseliny, retro-inverzn\u00ed orientace; molekulov\u00e1 hmotnost ~3 000 Da). Mechanismus: FOXO4 norm\u00e1ln\u011b ukotvuje p53 v j\u00e1d\u0159e senescentn\u00edch bun\u011bk, co\u017e jim umo\u017e\u0148uje unikat apopt\u00f3ze navzdory aktivn\u00ed signalizaci p53. FOXO4-DRI kompetitivn\u011b v\u00e1\u017ee transaktiva\u010dn\u00ed dom\u00e9nu p53, vyt\u011bs\u0148uje p\u0159irozen\u00e9 FOXO4 a uvol\u0148uje p53 k translokaci do mitochondri\u00ed \u2014 co\u017e spou\u0161t\u00ed selektivn\u00ed <strong>senol\u00fdza<\/strong> (apopt\u00f3za pouze senescentn\u00edch bun\u011bk). Pr\u016flomov\u00e1 v\u00fdzkumn\u00e1 l\u00e1tka pro \u201ccvi\u010den\u00ed senescence\u201d. Pouze pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> Lyofilizovan\u00fd \u226599% HPLC-verifikovan\u00fd FOXO4-DRI \u00b7 COA dostupn\u00e9 na vy\u017e\u00e1d\u00e1n\u00ed \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 expedice v\u00fdzkumn\u00fdch materi\u00e1l\u016f \u00b7 1 400+ ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px;\">Specifikace<\/th>\n<th style=\"padding: 8px 12px;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>T\u0159\u00edda slou\u010denin<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Syntetick\u00fd ~28-aa D-aminokyselinov\u00fd retro-inverzn\u00ed peptid; senolytick\u00e1 slou\u010denina; inhibitor protein-proteinov\u00e9 interakce p53-FOXO4<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Chemick\u00fd n\u00e1zev<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">FOXO4-DRI (alternativn\u00ed n\u00e1zvy: FOX04-DRI; FOXO4-D-Retro-Inverso; Baar\/Demaria\/de Keizer senolytick\u00fd peptid; ProxoFen \u2014 d\u0159\u00edv\u011bj\u0161\u00ed preklinick\u00fd n\u00e1zev)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>CAS \u010d\u00edslo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">V\u00fdzkumn\u00fd peptid \u2014 \u017e\u00e1dn\u00e9 \u0161iroce registrovan\u00e9 CAS \u010d\u00edslo; identifikace publikovanou sekvenc\u00ed (Baar et al. 2017) a dodavatelsk\u00fdm COA<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Sekvence (p\u0159\u00edm\u00e9 \u010dten\u00ed)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">LTLRKEPASEIAQSILEAYSQNGWANRRSAGGNTPS (p\u0159\u00edm\u00e9 po\u0159ad\u00ed \u010dten\u00ed; v\u0161ech 28 zbytk\u016f v <strong>D-aminokyselinov\u00e9 stereochemii<\/strong>, retro-inverzn\u00ed orientace v\u016f\u010di nativn\u00ed L-FOXO4 sekvenci). N\u011bkter\u00e9 publikovan\u00e9 varianty pou\u017e\u00edvaj\u00ed m\u00edrn\u011b odli\u0161nou d\u00e9lku fragmentu\/rozsah zbytk\u016f; konzultujte COA pro batch-specifickou sekvenci.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>item7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~3 000 Da (m\u00edrn\u011b se li\u0161\u00ed podle publikovan\u00e9 sekven\u010dn\u00ed varianty)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item2<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">D-retro-inverzn\u00ed peptid \u2014 sekven\u010dn\u011b odvozen\u00fd p\u0159ibli\u017en\u00fd MF C<sub>105<\/sub>H<sub>184<\/sub>N<sub>30<\/sub>O<sub>27<\/sub>; publikovan\u00e1 MW ~2 330 Da. P\u0159esn\u00fd vzorec se m\u00edrn\u011b li\u0161\u00ed mezi dodavatelsk\u00fdmi \u0161ar\u017eemi, proto\u017ee kanonick\u00e1 sekvence Baar 2017 byla replikov\u00e1na v\u00edce skupinami s men\u0161\u00edmi variantami bun\u011b\u010dn\u011b pronikaj\u00edc\u00edch peptidov\u00fdch linker\u016f.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Mechanismus \u00fa\u010dinku<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">V senescentn\u00edch bu\u0148k\u00e1ch nativn\u00ed FOXO4 v\u00e1\u017ee transaktiva\u010dn\u00ed dom\u00e9nu p53 a ukotvuje p53 v j\u00e1d\u0159e \u2014 \u010d\u00edm\u017e zabra\u0148uje p53 spustit apopt\u00f3zu navzdory bun\u011b\u010dn\u00e9mu po\u0161kozen\u00ed, kter\u00e9 p\u016fvodn\u011b p53 aktivovalo. To je jeden z d\u016fvod\u016f, pro\u010d senescentn\u00ed bu\u0148ky p\u0159e\u017e\u00edvaj\u00ed a hromad\u00ed se s v\u011bkem. <strong>FOXO4-DRI<\/strong> napodobuje vazebn\u00e9 rozhran\u00ed FOXO4 k p53, ale v retro-inverzn\u00ed orientaci s inverzn\u00ed stereochemi\u00ed \u2014 kompetitivn\u011b obsazuje vazebn\u00e9 m\u00edsto p53, vyt\u011bs\u0148uje nativn\u00ed FOXO4 a uvol\u0148uje p53. Uvoln\u011bn\u00fd p53 se translokuje do mitochondri\u00ed, kde spou\u0161t\u00ed <strong>intrinsickou apopt\u00f3zu<\/strong> prost\u0159ednictv\u00edm kask\u00e1dy zprost\u0159edkovan\u00e9 p53 zahrnuj\u00edc\u00ed Bax \/ Bak \/ uvoln\u011bn\u00ed cytochromu c. Selektivn\u00ed pro senescentn\u00ed bu\u0148ky, proto\u017ee maj\u00ed jak (a) FOXO4-v\u00e1zan\u00e9 p53, tak (b) ji\u017e aktivovan\u00e9 p53; nesenescentn\u00ed bu\u0148ky nemaj\u00ed ani jedno a nejsou ovlivn\u011bny.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>D-aminokyselinov\u00e1 stereochemie<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Retro-inverzn\u00ed design D-aminokyselin zaji\u0161\u0165uje odolnost v\u016f\u010di prote\u00e1z\u00e1m \u2014 hostitelsk\u00e9 prote\u00e1zy rozpozn\u00e1vaj\u00ed pouze L-aminokyseliny \u2014 co\u017e prodlu\u017euje polo\u010das in vivo a umo\u017e\u0148uje peror\u00e1ln\u00ed \/ intraperitone\u00e1ln\u00ed pod\u00e1v\u00e1n\u00ed v publikovan\u00fdch protokolech pro hlodavce.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Publikovan\u00e9 in vivo \u00fa\u010dinky (Baar 2017)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Selektivn\u00ed odstran\u011bn\u00ed senescentn\u00edch bun\u011bk u st\u00e1rnouc\u00edch my\u0161\u00ed; obnoven\u00ed hustoty a kvality srsti; obnoven\u00ed fyzick\u00e9 kondice \/ vytrvalosti p\u0159i b\u011bhu; obnoven\u00ed biomarker\u016f ren\u00e1ln\u00ed funkce; zlep\u0161en\u00ed v modelech po\u0161kozen\u00ed zprost\u0159edkovan\u00e9ho senescenc\u00ed indukovanou DOX. Tato studie p\u0159inesla jeden z nejcitovan\u011bj\u0161\u00edch d\u016fkaz\u016f, \u017ee odstran\u011bn\u00ed senescentn\u00edch bun\u011bk m\u016f\u017ee funk\u010dn\u011b omladit st\u00e1rnouc\u00ed organismy.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Forma \/ \u010cistota \/ Skladov\u00e1n\u00ed<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00fd b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd pr\u00e1\u0161ek, \u226599% HPLC. Skladov\u00e1n\u00ed kr\u00e1tkodob\u011b 2\u20138 \u00b0C, dlouhodob\u011b \u221220 \u00b0C. Rekonstituovan\u00fd roztok: 2\u20138 \u00b0C, pou\u017e\u00edt do 30 dn\u016f. Vyvarujte se opakovan\u00e9ho zmrazov\u00e1n\u00ed.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Pouze pro v\u00fdzkum<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed na seznamu zak\u00e1zan\u00fdch l\u00e1tek WADA. Preklinick\u00e1 v\u00fdzkumn\u00e1 slou\u010denina. Neexistuj\u00ed form\u00e1ln\u00ed klinick\u00e9 studie na lidech s FOXO4-DRI samotn\u00fdm; souvisej\u00edc\u00ed senolytick\u00e9 slou\u010deniny (dasatinib + kvercetin, fisetin, navitoklax) jsou samostatn\u011b ve f\u00e1zi transla\u010dn\u00edho v\u00fdzkumu.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Mechanismus \u00fa\u010dinku \u2014 selektivn\u00ed senol\u00fdza prost\u0159ednictv\u00edm naru\u0161en\u00ed interakce p53-FOXO4<\/h2>\n<p>FOXO4-DRI je kanonick\u00fd p\u0159\u00edklad v\u00fdzkumn\u00e9ho n\u00e1stroje pro <strong>peptidovou senolytickou farmakologii<\/strong>. Koncept senol\u00fdzy (selektivn\u00ed usmrcen\u00ed senescentn\u00edch bun\u011bk bez ovlivn\u011bn\u00ed norm\u00e1ln\u00edch bun\u011bk) je jedn\u00edm z nejcitovan\u011bj\u0161\u00edch sou\u010dasn\u00fdch r\u00e1mc\u016f pro anti-ageing terapie. Mechanistick\u00fd p\u0159\u00edb\u011bh FOXO4-DRI je neobvykle jasn\u00fd:<\/p>\n<ul>\n<li><strong>Senescentn\u00ed bu\u0148ky se hromad\u00ed se st\u00e1rnut\u00edm<\/strong> \u2014 Po\u0161kozen\u00ed tk\u00e1n\u011b, po\u0161kozen\u00ed DNA, oxida\u010dn\u00ed stres a dal\u0161\u00ed stresory spou\u0161t\u011bj\u00ed vstup bun\u011bk do senescentn\u00edho stavu (nevratn\u00e9 zastaven\u00ed bun\u011b\u010dn\u00e9ho cyklu s perzistuj\u00edc\u00edm SASP \u2014 fenotypem asociovan\u00fdm se senescenc\u00ed). Senescentn\u00ed bu\u0148ky se hromad\u00ed se st\u00e1rnut\u00edm a p\u0159isp\u00edvaj\u00ed k v\u011bkem podm\u00edn\u011bn\u00e9 dysfunkci tk\u00e1n\u00ed. Selektivn\u00ed odstran\u011bn\u00ed senescentn\u00edch bun\u011bk reverzuje mnoho v\u011bkem podm\u00edn\u011bn\u00fdch fenotyp\u016f v my\u0161\u00edch modelech.<\/li>\n<li><strong>FOXO4 v\u00e1\u017ee p53 v senescentn\u00edch bu\u0148k\u00e1ch<\/strong> \u2014 Senescentn\u00ed bu\u0148ky maj\u00ed zv\u00fd\u0161en\u00e9 hladiny p53 a aktivn\u00ed signalizaci p53. Norm\u00e1ln\u011b by p53 spustil apopt\u00f3zu. Ale v senescentn\u00edch bu\u0148k\u00e1ch transkrip\u010dn\u00ed faktor FOXO4 v\u00e1\u017ee p53 v j\u00e1d\u0159e, \u010d\u00edm\u017e ho tam ukotv\u00ed a zabr\u00e1n\u00ed jeho translokaci do mitochondri\u00ed, kde by jinak inicioval vnit\u0159n\u00ed apoptotickou kask\u00e1du. Toto ukotven\u00ed FOXO4-p53 je sou\u010d\u00e1st\u00ed mechanismu p\u0159e\u017eit\u00ed, kter\u00fd umo\u017e\u0148uje senescentn\u00edm bu\u0148k\u00e1m p\u0159etrv\u00e1vat.<\/li>\n<li><strong>FOXO4-DRI jako peptidomimetick\u00fd kompetitor<\/strong> \u2014 Peptid je navr\u017een tak, aby napodoboval vazebn\u00e9 rozhran\u00ed FOXO4 k p53, ale v retro-inverzn\u00ed orientaci D-aminokyselin. V\u00e1\u017ee p53 s podobnou afinitou jako nativn\u00ed FOXO4 \u2014 sout\u011b\u017e\u00ed o stejn\u00e9 vazebn\u00e9 m\u00edsto. L\u00e9\u010dba FOXO4-DRI kompetitivn\u011b vyt\u011bs\u0148uje nativn\u00ed FOXO4 z p53 v senescentn\u00edch bu\u0148k\u00e1ch.<\/li>\n<li><strong>Uvoln\u011bn\u00fd p53 \u2192 mitochondri\u00e1ln\u00ed apopt\u00f3za<\/strong> \u2014 Uvoln\u011bn\u00fd p53 ji\u017e nen\u00ed v\u00e1z\u00e1n k j\u00e1dru a translokuje do mitochondri\u00ed. Zde spou\u0161t\u00ed kanonickou p53-zprost\u0159edkovanou mitochondri\u00e1ln\u00ed apoptotickou kask\u00e1du (aktivace Bax\/Bak, uvoln\u011bn\u00ed cytochromu c, aktivace APAF-1\/kasp\u00e1za-9\/kasp\u00e1za-3). Bu\u0148ka podstupuje apopt\u00f3zu.<\/li>\n<li><strong>Selektivita pro senescentn\u00ed bu\u0148ky<\/strong> \u2014 Nesenescentn\u00ed bu\u0148ky bu\u010f nemaj\u00ed aktivovan\u00fd p53 (tedy \u017e\u00e1dn\u00fd spou\u0161t\u011b\u010d apopt\u00f3zy), nemaj\u00ed vazbu FOXO4 (tak\u017ee FOXO4-DRI nem\u00e1 co vyt\u011bsnit), nebo maj\u00ed oba rysy v mnohem ni\u017e\u0161\u00edch hladin\u00e1ch. FOXO4-DRI je proto ve studi\u00edch na my\u0161\u00edch vysoce selektivn\u00ed pro senescentn\u00ed bu\u0148ky.<\/li>\n<li><strong>Odolnost D-aminokyselinov\u00e9ho peptidu v\u016f\u010di prote\u00e1z\u00e1m<\/strong> \u2014 Retro-inverzn\u00ed konstrukce z D-aminokyselin chr\u00e1n\u00ed peptid p\u0159ed proteolytickou degradac\u00ed, prodlu\u017euje polo\u010das in vivo a umo\u017e\u0148uje IP\/or\u00e1ln\u00ed d\u00e1vkovac\u00ed re\u017eimy.<\/li>\n<\/ul>\n<h2>Publikovan\u00e9 v\u00fdzkumn\u00e9 aplikace<\/h2>\n<ul>\n<li><strong>Senolytick\u00e1 farmakologie \u2014 kanonick\u00fd p\u0159\u00edklad peptidu<\/strong> \u2014 nejcitovan\u011bj\u0161\u00ed peptidov\u00e9 senolytikum v publikovan\u00e9 literatu\u0159e<\/li>\n<li><strong>V\u00fdzkum biologie st\u00e1rnut\u00ed<\/strong> \u2014 selektivn\u00ed odstran\u011bn\u00ed senescentn\u00edch bun\u011bk z model\u016f st\u00e1rnouc\u00edch my\u0161\u00ed<\/li>\n<li><strong>Farmakologie interakce protein\u016f p53-FOXO4<\/strong> \u2014 u\u017eite\u010dn\u00e1 referen\u010dn\u00ed slou\u010denina pro \u0161ir\u0161\u00ed biologii vazby p53<\/li>\n<li><strong>V\u00fdzkum chemoterapi\u00ed indukovan\u00e9 senescence (TIS)<\/strong> \u2014 modely senescence indukovan\u00e9 DOX, clearance senescentn\u00edch bun\u011bk po chemoterapii<\/li>\n<li><strong>V\u00fdzkum regenerace tk\u00e1n\u00ed<\/strong> \u2014 obnova hustoty srsti, vytrvalosti p\u0159i b\u011bhu, ren\u00e1ln\u00ed funkce u st\u00e1rnouc\u00edch my\u0161\u00ed (parametry dle Baar 2017)<\/li>\n<li><strong>Komparativn\u00ed v\u00fdzkum senolytik<\/strong> \u2014 vs mal\u00e9 molekuly senolytik (dasatinib + kvercetin, fisetin, navitoklax, ABT-263)<\/li>\n<li><strong>N\u00e1vrh retro-inverzn\u00edch peptid\u016f z D-aminokyselin<\/strong> \u2014 p\u0159\u00edklad strategie designu rezistentn\u00ed na prote\u00e1zy<\/li>\n<\/ul>\n<p>Pro \u0161ir\u0161\u00ed kontext viz <a href=\"https:\/\/medsbase.com\/cs\/epitalon\/\">Epitalon<\/a> (Khavinson\u016fv tetrapeptid pine\u00e1ln\u00ed osy \u2014 v\u00fdzkum dlouhov\u011bkosti), <a href=\"https:\/\/medsbase.com\/cs\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> (mitochondri\u00e1ln\u011b c\u00edlen\u00fd antioxidant), <a href=\"https:\/\/medsbase.com\/cs\/mots-c\/\">MOTS-c<\/a> (mitochondri\u00e1ln\u00ed peptid), <a href=\"https:\/\/medsbase.com\/cs\/5-amino-1mq\/\">5-Amino-1MQ<\/a> (inhibitor NNMT na ose NAD). Prohl\u00e9dn\u011bte si cel\u00fd <a href=\"https:\/\/medsbase.com\/cs\/peptides\/\">katalog peptidov\u00e9ho v\u00fdzkumu<\/a>, nebo nav\u0161tivte kur\u00e1torsk\u00fd <a href=\"https:\/\/medsbase.com\/cs\/best-longevity-peptides\/\">v\u00fdzkumn\u00e9 slou\u010deniny pro dlouhov\u011bkost<\/a> .<\/p>\n<h2>Dostupn\u00e9 s\u00edly<\/h2>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px;\">S\u00edla vialky<\/th>\n<th style=\"padding: 10px;\">Velikosti balen\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong> \u2014 standardn\u00ed v\u00fdzkumn\u00e1 s\u00edla pro in-vivo senolytick\u00e9 protokoly a modely n\u00e1dorem indukovan\u00e9 senescence (TIS); nejni\u017e\u0161\u00ed cena na mg u balen\u00ed 20 vial<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Pot\u0159ebujete BAC vodu?<\/strong> Rekonstituce jak\u00e9hokoli lyofilizovan\u00e9ho vialu vy\u017eaduje steriln\u00ed bakteriostatickou vodu. Sp\u00e1rujte tento produkt s na\u0161\u00edm <a href=\"\/cs\/bac-water\/\"><strong>BAC Water (Bakteriostatick\u00e1 voda)<\/strong><\/a> \u2014 30 mL multid\u00e1vkov\u00fdm vialem, 0,9% benzylalkoholem konzervovan\u00fdm, USP-grade.<\/div>\n<h2>Skladov\u00e1n\u00ed a rekonstituce<\/h2>\n<p>Lyofilizov\u00e1no pro kr\u00e1tkodob\u00e9 skladov\u00e1n\u00ed p\u0159i 2\u20138 \u00b0C, pro dlouhodob\u00e9 skladov\u00e1n\u00ed p\u0159i \u221220 \u00b0C. Rekonstituujte bakteriostatickou vodou (1,0 mL na 10 mg lahvi\u010dku \u2192 10 mg\/mL). Vyvarujte se opakovan\u00e9mu zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed.<\/p>\n<h2>\u010casto kladen\u00e9 ot\u00e1zky<\/h2>\n<h3>Je FOXO4-DRI tot\u00e9\u017e co FOX04-DRI?<\/h3>\n<p>Ano \u2014 \u201cFOX04-DRI\u201d je b\u011b\u017en\u00e1 alternativn\u00ed varianta z\u00e1pisu, kde je p\u00edsmeno \u201cO\u201d nahrazeno \u010d\u00edslic\u00ed \u201c0\u201d. Peptid je spr\u00e1vn\u011b pojmenov\u00e1n podle transkrip\u010dn\u00edho faktoru FOXO4 (Forkhead box O4). Ob\u011b varianty ozna\u010duj\u00ed stejn\u00fd senolytick\u00fd peptid z pr\u00e1ce Baar\/de Keizer\/Demaria z roku 2017 publikovan\u00e9 v \u010dasopise Cell.<\/p>\n<h3>Jak\u00e9 d\u00e1vkov\u00e9 rozsahy byly pou\u017eity v publikovan\u00fdch v\u00fdzkumech?<\/h3>\n<p>V pr\u00e1ci Baar z roku 2017 bylo pou\u017eito 1\u20135 mg\/kg intraperitone\u00e1ln\u011b t\u0159ikr\u00e1t t\u00fddn\u011b v 4t\u00fddenn\u00edch cyklech u st\u00e1rnouc\u00edch my\u0161\u00ed. Jin\u00e9 publikovan\u00e9 protokoly pou\u017e\u00edvaj\u00ed d\u00e1vkov\u00e1n\u00ed 1\u201310 mg\/kg v z\u00e1vislosti na modelu a c\u00edlov\u00e9m parametru. In-vitro pr\u00e1ce pou\u017e\u00edvaj\u00ed mikromol\u00e1rn\u00ed koncentrace peptidu.<\/p>\n<h3>Pro\u010d D-aminokyselinov\u00e1 retro-inverzn\u00ed struktura?<\/h3>\n<p>Retro-inverzn\u00ed struktura slo\u017een\u00e1 v\u00fdhradn\u011b z D-aminokyselin poskytuje t\u00e9m\u011b\u0159 \u00faplnou odolnost v\u016f\u010di prote\u00e1z\u00e1m \u2014 hostitelsk\u00e9 peptid\u00e1zy rozpozn\u00e1vaj\u00ed pouze L-aminokyseliny. To prodlu\u017euje plazmatick\u00fd polo\u010das na hodiny a umo\u017e\u0148uje praktick\u00e9 in-vivo d\u00e1vkovac\u00ed protokoly, kter\u00e9 by nebyly provediteln\u00e9 s p\u0159irozenou sekvenc\u00ed FOXO4 slo\u017eenou z L-aminokyselin (kter\u00e1 by byla degradov\u00e1na b\u011bhem minut).<\/p>\n<h3>Byl FOXO4-DRI testov\u00e1n v klinick\u00fdch studi\u00edch na lidech?<\/h3>\n<p>Nejsou dokon\u010deny \u017e\u00e1dn\u00e9 form\u00e1ln\u00ed klinick\u00e9 studie f\u00e1ze I\/II s FOXO4-DRI konkr\u00e9tn\u011b. Tato slou\u010denina z\u016fst\u00e1v\u00e1 preklinick\u00fdm v\u00fdzkumn\u00fdm n\u00e1strojem. Jin\u00e9 senolytick\u00e9 l\u00e1tky (dasatinib + kvercetin, fisetin) jsou samostatn\u011b p\u0159edm\u011btem klinicko-transla\u010dn\u00edho v\u00fdzkumu.<\/p>\n<h3>Jak\u00fd je vztah mezi FOXO4-DRI a jin\u00fdmi senolytiky?<\/h3>\n<p>FOXO4-DRI je kanonick\u00fd peptidov\u00fd senolytikum. Mezi dal\u0161\u00ed hlavn\u00ed t\u0159\u00eddy senolytik pat\u0159\u00ed: (a) kombinace tyrosinkin\u00e1z\/BCL-2 rodiny (dasatinib + kvercetin); (b) flavonoidy (fisetin); (c) BH3 mimetika (navitoklax\/ABT-263); (d) dal\u0161\u00ed intervence v p53-FOXO4 dr\u00e1ze. Mechanismy se \u010d\u00e1ste\u010dn\u011b p\u0159ekr\u00fdvaj\u00ed, ale c\u00edl\u00ed na r\u016fzn\u00e9 aspekty p\u0159e\u017eit\u00fdch drah senescentn\u00edch bun\u011bk.<\/p>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 20px 0 8px; border-radius: 4px; font-size: 14px;\"><strong>Pro\u010d objedn\u00e1vat v\u00fdzkumn\u00e9 slou\u010deniny od MedsBase:<\/strong> Lyofilizovan\u00e9 peptidy a slou\u010deniny HPLC \u226599% \u00b7 COA dostupn\u00e9 na vy\u017e\u00e1d\u00e1n\u00ed \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava \u00b7 <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance<\/a> na ka\u017edou objedn\u00e1vku \u00b7 1,400+ ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Dal\u0161\u00ed peptidy pro v\u00fdzkum dlouhov\u011bkosti\/st\u00e1rnut\u00ed<\/h2>\n<ul>\n<li><a href=\"\/cs\/epitalon\/\"><strong>Epitalon<\/strong><\/a> \u2014 Khavinson\u016fv tetrapeptidov\u00fd bioregul\u00e1tor pine\u00e1ln\u00ed osy<\/li>\n<li><a href=\"\/cs\/ss-31-elamipretide\/\"><strong>SS-31 (Elamipretide)<\/strong><\/a> \u2014 Kardiolipin-v\u00e1zaj\u00edc\u00ed mitochondri\u00e1ln\u011b c\u00edlen\u00fd antioxida\u010dn\u00ed peptid<\/li>\n<li><a href=\"\/cs\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Metabolick\u00fd peptid odvozen\u00fd z mitochondri\u00ed<\/li>\n<li><a href=\"\/cs\/5-amino-1mq\/\"><strong>5-Amino-1MQ<\/strong><\/a> \u2014 Inhibitor NNMT \u2013 \u0161et\u0159\u00edc\u00ed prekurzor NAD-osy<\/li>\n<li><a href=\"\/cs\/nad\/\"><strong>NAD\u207a<\/strong><\/a> \u2014 P\u0159\u00edm\u00e1 suplementace dinukleotidov\u00e9ho poolu<\/li>\n<li><a href=\"\/cs\/bac-water\/\"><strong>BAC Water (Bakteriostatick\u00e1 voda)<\/strong><\/a> \u2014 Nezbytn\u00e9 pro rekonstituci jak\u00e9hokoli lyofilizovan\u00e9ho vialu \u2014 steriln\u00ed \u0159edidlo s 0,9% konzervantem benzylalkoholu<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Syntetick\u00fd ~28-aa D-aminokyselinov\u00fd peptid<br \/>\n\u2705 Indukuje disociaci FOXO4-p53 \u2192 translokaci p53 do mitochondri\u00ed \u2192 apopt\u00f3zu senescentn\u00edch bun\u011bk<br \/>\n\u2705 Selektivn\u00ed senol\u00fdza: \u0161et\u0159\u00ed nesenescentn\u00ed bu\u0148ky; rezistentn\u00ed na prote\u00e1zu d\u00edky n\u00e1vrhu D-AA<br \/>\n\u2705 Selektivn\u00ed senol\u00fdza: \u0161et\u0159\u00ed nesenescentn\u00ed bu\u0148ky; rezistentn\u00ed v\u016f\u010di prote\u00e1z\u00e1m d\u00edky D-AA designu<br \/>\n\u2705 Senolytika: \u0161et\u0159\u00ed nesenescentn\u00ed bu\u0148ky; rezistentn\u00ed na prote\u00e1zu d\u00edky n\u00e1vrhu D-AA<\/p>\n<p><strong>FOXO4-DRI<\/strong> \u2705 MW ~3 000 Da; kanonick\u00fd peptid senolytick\u00e9ho v\u00fdzkumn\u00e9ho n\u00e1stroje.<\/p>","protected":false},"featured_media":71534,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6569,6568,6565,6564,6567,6494,6570,6566],"class_list":{"0":"post-71515","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-anti-ageing-research","8":"product_tag-d-retro-inverso-peptide","9":"product_tag-fox04-dri","10":"product_tag-foxo4-dri","11":"product_tag-p53-foxo4-inhibitor","12":"product_tag-research-peptide","13":"product_tag-senescent-cell-clearance","14":"product_tag-senolytic-peptide","16":"first","17":"instock","18":"shipping-taxable","19":"purchasable","20":"product-type-variable","21":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/71515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=71515"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/71534"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=71515"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=71515"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=71515"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=71515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}